Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 2/20 | 0.39 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597654 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1RAB9AMAPTKMT2A | |
| SCHEMBL4595759 | 0.99 | L3MBTL1 (0.44) | SMN1; SMN2L3MBTL1RAB9AMAPTKMT2A | |
| SCHEMBL4595768 | 0.99 | L3MBTL1 (0.44) | SMN1; SMN2L3MBTL1RAB9AMAPTKMT2A | |
| SCHEMBL4596864 | 0.82 | KMT2A (0.44) | SMN1; SMN2L3MBTL1KMT2AMCL1POLB | |
| SCHEMBL4596853 | 0.82 | KMT2A (0.44) | SMN1; SMN2L3MBTL1KMT2AMCL1POLB | |
| SCHEMBL4596857 | 0.82 | KMT2A (0.44) | SMN1; SMN2L3MBTL1KMT2AMCL1POLB | |
| SCHEMBL4595627 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1RAB9AMAPTKMT2A | |
| SCHEMBL4597700 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1RAB9AMAPTKMT2A | |
| SCHEMBL4597353 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1RAB9AMAPTKMT2A | |
| SCHEMBL4597158 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1RAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908752-B2 | Process for the preparation of the enant iomeric forms of 2-substituted 2- (2, 5-dioxoimidazolidin-1yl) -acetic acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-21 | — | — | US | disclosed |
| EP-1506177-A2 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030054507-A1 | Process for the preparation of the enant iomeric forms of 2-substituted 2- (2, 5-dioxoimidazolidin-1-yl) -acetic acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003008386-A2 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF 2-SUBSTITUTED 2-(2,5-DIOXOIMIDAZOLIDIN-1-YL)-ACETIC ACID DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |